Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis

Overview

The proposed study is an open-label, single-center, single arm phase 1b study to evaluate the safety and efficacy of radiotherapy plus sintilimab for HCC with PVTT.

Full Title of Study: “A Pilot Study to Evaluate the Safety and Efficacy of Radiotherapy Plus Sintilimab for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 31, 2021

Detailed Description

The patients were divided into two groups. The first group: the single dose of radiotherapy was 200 cGy, once a day, the total dose was 5000 cGy. The second group: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy.

Interventions

  • Radiation: Radiotherapy
    • Arm 1: The single radiotherapy dose was 200cGy, once a day, and the total dose was 5000cGy. Arm 2: the single dose of radiotherapy was 300 cGy, once a day, and the total dose was 3000 cGy.
  • Drug: Sintilimab
    • Sintilimab is a PD-1 inhibitor, intravenously, at a dose of 200 mg, once every 3 weeks

Arms, Groups and Cohorts

  • Experimental: Radiotherapy Plus Sintilimab
    • HCC Patients will be received radiotherapy and concurrent Sintilimab (PD-1 inhibitor)treatment.

Clinical Trial Outcome Measures

Primary Measures

  • Incidence of treatment-emergent adverse events
    • Time Frame: 1 year
    • Safety and tolerability of radiotherapy plus sintilimab based on NCI CTCAE v4.03 and RTOG/EORTC criteria

Secondary Measures

  • Overall response rate (ORR)
    • Time Frame: 1 year
    • Objective response rate based on RECIST v1.1 criteria
  • Progression-free survival (PFS)
    • Time Frame: 2 years
  • Overall Survival (OS)
    • Time Frame: 2 years

Participating in This Clinical Trial

Inclusion Criteria

1. Ability to understand and willingness to sign a written informed consent document. 2. Locally advanced hepatocellular carcinoma with identified tumor thrombosis of main portal vein or primary branches (left and / or right branches) 3. Has at least 1 measurable lesion 4. Age ≥18 years 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 6. Adequate organ function 7. Child Pugh class A 8. Life expectancy ≥12 weeks. 9. Antiviral therapy per local standard of care for hepatitis B 10. Woman of child bearing potential must have a negative pregnancy test 11. Must use acceptable form of birth control while on study Exclusion Criteria:

1. Has previously been performed by raditotherapy for the area to be treated. 2. With extrahepatic metastasis 3. History of hepatic encephalopathy or liver transplantation 4. Untreated hepatitis infection: HBV DNA>2000IU/mlor10000 copy/ml, HCV RNA> 1000copy/ml, both HbsAg and anti-HCV body are positive 5. Has liver tumor not amenable to radiotherapy, or has had prior upper abdominal radiation therapy within planned volumes 6. Has had esophageal or gastric variceal bleeding within 3 months prior to study enrollment 7. With serious systemic diseases such as heart disease and cerebrovascular disease, and the condition is unstable or uncontrollable 8. Evidence of active pulmonary tuberculosis (TB) 9. Positive test of immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) 10. History of allergic reactions to related drugs

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 100 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Beijing Tsinghua Chang Gung Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Gong Li, MD, Principal Investigator, Beijing Tsinghua Changgeng Hospital
  • Overall Contact(s)
    • Gong Li, MD, 0086-10-56119427, dr_gongli@163.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.